Neffy ® (epinephrine nasal spray) 1 mg is now available for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 years and older weighing 15 to ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.